title: Alpha adrenergic modulation on effects of norepinephrine transporter inhibitor reboxetine in five-choice serial reaction time task.
abstract: The study examined the effects of a norepinephrine transporter (NET) inhibitor reboxetine (RBX) on an attentional performance test. Adult SD rats trained with five-choice serial reaction time task (5-CSRTT) were administered with RBX (0, 3.0 and 10 mg/kg) in the testing day. Alpha-1 adrenergic receptor antagonist PRA and alpha-2 adrenergic receptor antagonist RX821002 were used to clarify the RBX effect. Results revealed that rat received RBX at 10 mg/kg had an increase in the percentage of the correct response and decreases in the numbers of premature response. Alpha-1 adrenergic receptor antagonist Prazosin (PRA) at 0.1 mg/kg reversed the RBX augmented correct responding rate. However, alpha-2 adrenergic receptor antagonist RX821002 at 0.05 and 0.1 mg/kg dose dependently reversed the RBX reduced impulsive responding. Our results suggested that RBX as a norepinephrine transporter inhibitor can be beneficial in both attentional accuracy and response control and alpha-1 and alpha-2 adrenergic receptors might be involved differently.
authors.affiliation: Dept of Physiology and Biophysics, National Defense Medical Center, Taiwan, Republic of China. yiaping@ms75.hinet.net
authors.forename: Yia-Ping
authors.initials: YP
authors.lastname: Liu
authors.forename: Yu-Lung
authors.initials: YL
authors.lastname: Lin
authors.forename: Chia-Hsin
authors.initials: CH
authors.lastname: Chuang
authors.forename: Yu-Cheng
authors.initials: YC
authors.lastname: Kao
authors.forename: Shang-Tang
authors.initials: ST
authors.lastname: Chang
authors.forename: Che-Se
authors.initials: CS
authors.lastname: Tung
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology*; D058668:Adrenergic alpha-1 Receptor Antagonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000818:Animals; D001288:Attention / Q000187:drug effects*; D004192:Discrimination, Psychological / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D005247:Feeding Behavior / Q000187:drug effects; D019329:Idazoxan / Q000031:analogs & derivatives / Q000494:pharmacology; D007175:Impulsive Behavior; D008297:Male; D009025:Morpholines / Q000494:pharmacology*; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000037:antagonists & inhibitors*; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011930:Reaction Time / Q000187:drug effects*; D000077593:Reboxetine; D018340:Receptors, Adrenergic, alpha-1 / Q000502:physiology*; D018341:Receptors, Adrenergic, alpha-2 / Q000502:physiology*; D013037:Spatial Behavior / Q000187:drug effects; D013998:Time Perception / Q000187:drug effects
chemical_list: D018759:Adrenergic Uptake Inhibitors; D058668:Adrenergic alpha-1 Receptor Antagonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D009025:Morpholines; D050484:Norepinephrine Plasma Membrane Transport Proteins; D018340:Receptors, Adrenergic, alpha-1; D018341:Receptors, Adrenergic, alpha-2; C493226:Slc6a2 protein, rat; D000077593:Reboxetine; C058525:2-methoxyidazoxan; D011224:Prazosin; D019329:Idazoxan
references.citation: Pharmacol Res. 2001 Sep;44(3):195-208
references.pmid: 11529686
references.citation: Pharmacol Biochem Behav. 1997 Apr;56(4):705-12
references.pmid: 9130297
references.citation: Neuroscience. 2006 Feb;137(3):1039-49
references.pmid: 16298081
references.citation: Biol Psychiatry. 2000 May 1;47(9):818-29
references.pmid: 10812041
references.citation: Depress Anxiety. 2005;21(2):78-89
references.pmid: 15884090
references.citation: Curr Opin Psychiatry. 2007 May;20(3):255-61
references.pmid: 17415079
references.citation: Occup Ther Int. 2005;12(4):218-33
references.pmid: 16485509
references.citation: Behav Brain Res. 1983 Sep;9(3):361-80
references.pmid: 6639741
references.citation: Psychiatry Res. 1998 Dec 14;81(3):309-22
references.pmid: 9925182
references.citation: J Exp Psychol. 1963 Oct;66:332-7
references.pmid: 14051850
references.citation: Psychopharmacology (Berl). 2002 Oct;163(3-4):362-80
references.pmid: 12373437
references.citation: Eur J Pharmacol. 1999 Aug 27;379(2-3):125-33
references.pmid: 10497898
references.citation: Pharmacol Biochem Behav. 1993 May;45(1):123-9
references.pmid: 8100071
references.citation: J Am Acad Child Adolesc Psychiatry. 1996 Mar;35(3):264-72
references.pmid: 8714313
references.citation: J Affect Disord. 2006 May;92(1):71-8
references.pmid: 16458363
references.citation: Eur J Neurosci. 2000 Aug;12(8):3051-8
references.pmid: 10971646
references.citation: Ann N Y Acad Sci. 2006 Jul;1071:521-4
references.pmid: 16891611
references.citation: Psychopharmacology (Berl). 2003 Jan;165(2):136-45
references.pmid: 12420150
references.citation: J Clin Psychiatry. 2006;67 Suppl 8:32-8
references.pmid: 16961428
references.citation: Psychopharmacology (Berl). 1998 Aug;138(3-4):231-59
references.pmid: 9725746
references.citation: Brain Res Bull. 1994;35(5-6):451-5
references.pmid: 7859102
references.citation: J Clin Psychopharmacol. 2006 Apr;26(2):121-7
references.pmid: 16633139
references.citation: J Neurosci Methods. 2005 Apr 15;143(1):79-85
references.pmid: 15763139
references.citation: J Affect Disord. 2005 Dec;89(1-3):125-35
references.pmid: 16324752
references.citation: Behav Brain Res. 1989 Jun 1;33(2):165-79
references.pmid: 2504222
references.citation: Pharmacol Biochem Behav. 1997 Jan;56(1):31-40
references.pmid: 8981606
references.citation: Psychosomatics. 2005 Sep-Oct;46(5):379-84
references.pmid: 16145181
references.citation: Psychopharmacology (Berl). 1987;91(4):458-66
references.pmid: 3108926
references.citation: Circulation. 2003 Jun 17;107(23):2949-54
references.pmid: 12796139
references.citation: Drugs Future. 2004 Dec;29(12):1235-1244
references.pmid: 16871320
references.citation: Psychopharmacology (Berl). 1992;106(2):228-34
references.pmid: 1532259